In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cumberland Pharmaceuticals nets $79mm in IPO

Executive Summary

Two years after filing, specialty pharmaco Cumberland Pharmaceuticals has completed its initial public offering, netting $79mm through the sale of 5mm shares at $17. (The company had originally planned to sell 6.25mm shares priced between $14 and $16 each, but last month in an amended S-1 filing it dropped the number of shares to 5mm and upped the target price to between $19 and $21.)
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies